Journal
ANTIVIRAL THERAPY
Volume 15, Issue 8, Pages 1077-1086Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1681
Keywords
-
Categories
Funding
- HAART Oversight Committee
- Abbott Laboratories
- AIDS Treatment Activists Coalition
- Boehringer-Ingelheim Pharmaceuticals, Inc.
- European AIDS Treatment Group
- US Food and Drug Administration
- F Hoffmann La Roche, Ltd
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Merck Co., Inc.
- Pfizer, Inc.
- Tibotec
- Health Insurance Fund Council (Amstelveen, the Netherlands) [CURE/97/46486]
- Agence Nationale de Recherches sur le SIDA et les hepatites virales
- Aquitaine Cohort
- Australian Government Department of Health and Ageing
- US National Institutes of Health's National Institute of Allergy and Infectious Diseases [UOI069907]
- Fondo de Investigacion Sanitaria [FIS 99/0887]
- Fundacion para la Investigacion y la Prevencion del SIDA en Espana [FIPSE 3171/00]
- National Institute of Allergy and Infectious Diseases and National Institutes of Health [5U01AI042170-10, 5U01AI046362-03]
- European Commission [CT94-1637, CT97-2713, QLK2-2000-00773, LSHP-CT-2006-018632]
- Bristol-Myers Squibb
- Roche
- Gilead Sciences
- Pfizer
- Merck Co.
- Boehringer Ingelheim
- Swiss Federal Office for Education and Science (EuroSIDA)
- Janssen-Cilag
- Swiss National Science Foundation
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI042170, U01AI046362] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: 01 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV-seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available